1,121 results on '"Planchard, D."'
Search Results
2. Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort
3. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
4. Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib
5. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
6. Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study
7. Small cell lung cancer: a slightly less orphan disease after immunotherapy
8. Autres cibles addictives (KRAS, RET, HER2, NTRK...)
9. Autres cibles addictives (KRAS, RET, HER2, NTRK…): Other addictive targets (KRAS, RET, HER2, NTRK…)
10. Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
11. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
12. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
13. Place de l’immunothérapie dans le cancer bronchique non à petites cellules localement avancé
14. Osimertinib chez les patients atteint d’un cancer bronchique non à petites cellules (CBNPC) muté EGFR présentant des métastases cérébrales ou leptoméningées: résultats de l’étude IFCT-1804 ORBITAL
15. Essai randomisé contrôlé comparant l’association pembrolizumab plus chimiothérapie à la chimiothérapie seule dans le mésothéliome pleural avancé, non prétraité (essai IND. 227, IFCT-1901)
16. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
17. CO175 OCTOPUS: Ambispective Observational Study Describing Diagnosis and Treatment Patterns in Adults with Metastatic NSCLC with BRAF V600E Mutation in Clinical Practice, to Assess Treatment Effectiveness and Quality of Life (TIP)
18. P2.04-03 EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 ± Anti-cancer Agents in Advanced Solid Tumours
19. MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02
20. P2.09-18 FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions
21. P1.23-07 Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study
22. P2.07-05 Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry
23. P1.22-19 Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions
24. P1.22-20 High Incidence of Ischemic Stroke in Patients with Non-small cell lung cancer and RET fusions
25. 80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
26. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
27. Autres cibles addictives (KRAS, RET, HER2, NTRK…)
28. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
29. CBNPC et autres cibles thérapeutiques (BRAF, HER2, MET, RET, NTRK...)
30. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
31. The role of brigatinib in crizotinib-resistant non-small cell lung cancer
32. Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA
33. Cancer bronchique non à petites cellules avec anomalies moléculaires actionnables (KRAS, BRAF, MET, fusions): Non-Small Cell Lung Cancer with Actionable Driver Mutations (KRAS, BRAF, MET, Fusions)
34. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
35. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
36. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
37. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
38. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
39. 5O Deciphering resistance mechanisms in cancer: Insights from the final report of MATCH-R study with focus on molecular drivers
40. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
41. P4.17F.03 Utilizing AI for Automated Data Entry and Analysis to Pre-Screen Lung Cancer Clinical Trial Candidates.
42. P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC.
43. P1.08B.02 Circulating T-Cell Immunosenescence in Patients with Unresectable Locally Advanced NSCLC: Preliminary Results of the SENLOAD Study.
44. MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed.
45. OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1.
46. PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations.
47. PL04.04 Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC.
48. 4P FDG PET derived metabolic tumor volume (MTV) and its transcriptomic correlates as biomarker to predict efficacy of immune checkpoint inhibitors (ICB) alone or in combination with chemotherapy in advanced NSCLC: A multicentric study
49. 259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota
50. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.